ARL11 and cutaneous mastocytosis: Among all candidates, GEPIA and OncoLnc survival tools also show that a higher expression of ARL11 is significantly associated with an improved prognosis of CM patients, agreeing with the survival analysis performed using TCGA data (Figures S7 and S8).